Fox Chase Cancer Center News

PHILADELPHIA (March 10, 2020) — A 10-year update of a randomized, prospective study conducted by researchers at Fox Chase Cancer Center has found that conventional fractionated and moderate hypofractionated radiation therapy for localized prostate cancer were equally effective.

PHILADELPHIA (March 6, 2020) – Newly elected fellows will be honored at the Society of Behavioral Health’s 2020 Annual Meeting & Scientific Sessions, being held April 1-4 in San Francisco.

PHILADELPHIA (March 2, 2020) – March is National Colorectal Cancer Awareness Month, and Fox Chase Cancer Center encourages individuals to schedule their colorectal cancer screening, such as a colonoscopy or fecal immunochemical testing (FIT).

PHILADELPHIA (March 2, 2020) – New research from Fox Chase Cancer Center indicates that starting chemotherapy before surgery does not expedite the start or completion of treatment for breast cancer as compared with performing surgery first, as some have previously believed.

PHILADELPHIA (February 28, 2020) – To more accurately reflect the mission and vision of the program, Fox Chase Cancer Center recently announced that the name of the Pain and Palliative Care Program has been changed to the Supportive Oncology and Palliative Care Program (SOPCP).

PHILADELPHIA (February 27, 2020) – On Sunday, March 22, patients, survivors, and their families will join faculty, staff, and volunteers as members of the Fox Chase team in the Colon Cancer Coalition’s annual Get Your Rear in Gear colon cancer run/walk in Philadelphia.

PHILADELPHIA (February 27, 2020) – Eileen K. Jaffe, PhD, a professor in the Molecular Therapeutics program at Fox Chase Cancer Center, was recently tapped to help write the book "Oligomerization in Health and Disease: From Enzymes to G Protein-Couple Receptors."

PHILADELPHIA (February 25, 2020) – Vladimir Kolenko, MD, PhD, received the two-year $200,000 NCI grant to target cholesterol homeostasis using genetic and pharmacological approaches in order to reinstate or re-emphasize sensitivity of prostate cancer cells to anti-androgens like abiraterone and enzalutamide.